Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)
Terns Pharmaceuticals (Nasdaq: TERN) announced the grant of equity inducement awards to a new employee under its 2022 Employment Inducement Award Plan. The company granted stock options to purchase 250,000 shares at an exercise price of $4.46 per share, which was the closing price on January 31, 2025. The options have a 10-year term and vest over four years, contingent on continued employment. The grant was approved by the Compensation Committee in compliance with Nasdaq Listing Rule 5635(c)(4) and serves as a material inducement for the employee's acceptance of employment.
Terns Pharmaceuticals (Nasdaq: TERN) ha annunciato l'assegnazione di premi azionari per incentivare un nuovo dipendente ai sensi del suo Piano di Assunzione per Premi Induttivi del 2022. L'azienda ha concesso opzioni su azioni per l'acquisto di 250.000 azioni a un prezzo di esercizio di 4,46 $ per azione, che corrisponde al prezzo di chiusura del 31 gennaio 2025. Le opzioni hanno un termine di 10 anni e maturano in quattro anni, a condizione di un impiego continuativo. L'assegnazione è stata approvata dal Comitato per la Compensazione in conformità alla Regola di Quotazione Nasdaq 5635(c)(4) e rappresenta un'importante incentivazione per l'accettazione dell'impiego da parte del dipendente.
Terns Pharmaceuticals (Nasdaq: TERN) anunció la concesión de premios en acciones como incentivo para un nuevo empleado bajo su Plan de Concesión de Incentivos Laborales de 2022. La compañía otorgó opciones sobre acciones para comprar 250.000 acciones a un precio de ejercicio de 4,46 $ por acción, que fue el precio de cierre del 31 de enero de 2025. Las opciones tienen un plazo de 10 años y se adquirirán durante cuatro años, condicionadas a la continuidad del empleo. La concesión fue aprobada por el Comité de Compensación de acuerdo con la Regla de Cotización de Nasdaq 5635(c)(4) y sirve como un incentivo material para la aceptación del empleo por parte del nuevo trabajador.
Terns Pharmaceuticals (Nasdaq: TERN)은 2022 고용 유인 보상 계획에 따라 새로운 직원에게 주식 유인 보상을 부여했다고 발표했습니다. 회사는 250,000주를 매입할 수 있는 주식 옵션을 주당 4.46달러의 행사 가격으로 부여했으며, 이는 2025년 1월 31일의 종가와 일치합니다. 옵션은 10년의 기간을 가지며, 고용이 계속되는 조건 하에 4년 동안 발생합니다. 이 보상은 Nasdaq 상장 규칙 5635(c)(4)에 따라 보상 위원회에 의해 승인되었고 직무 수락에 대한 중대한 유인으로 작용합니다.
Terns Pharmaceuticals (Nasdaq: TERN) a annoncé l'octroi de prix d'incitation en actions à un nouvel employé dans le cadre de son Plan d'Octroi d'Incitations à l'Emploi 2022. La société a accordé des options d'achat d'actions sur 250.000 actions à un prix d'exercice de 4,46 $ par action, qui correspond au prix de clôture du 31 janvier 2025. Les options ont un terme de 10 ans et prennent effet sur quatre ans, sous réserve d'une continuité d'emploi. L'octroi a été approuvé par le Comité de Rémunération conformément à la règle de cotation Nasdaq 5635(c)(4) et représente une incitation matérielle pour l'acceptation de l'emploi par l'employé.
Terns Pharmaceuticals (Nasdaq: TERN) hat die Gewährung von Aktieninduktionsprämien an einen neuen Mitarbeiter im Rahmen seines Plans zur Beschäftigungsinduktion 2022 bekannt gegeben. Das Unternehmen gewährte Aktienoptionen zum Kauf von 250.000 Aktien zu einem Ausübungspreis von 4,46 $ pro Aktie, was dem Schlusskurs vom 31. Januar 2025 entspricht. Die Optionen haben eine Laufzeit von 10 Jahren und werden über einen Zeitraum von vier Jahren fällig, sofern das Beschäftigungsverhältnis fortgesetzt wird. Die Gewährung wurde vom Vergütungsausschuss in Übereinstimmung mit der Nasdaq-Listing-Regel 5635(c)(4) genehmigt und dient als wesentliche Anreiz für die Annahme der Stelle durch den Mitarbeiter.
- None.
- None.
FOSTER CITY, Calif., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that it has granted as of February 1, 2025 an equity inducement award to a new employee under the terms of the 2022 Employment Inducement Award Plan, as amended (the “Inducement Plan”). The equity award was approved by the Compensation Committee of the Company’s Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4) and was made as a material inducement to the employee’s acceptance of employment with Terns.
The Company granted options to purchase 250,000 shares of Terns common stock to the new employee. The options have a 10-year term and an exercise price per share equal to
About Terns Pharmaceuticals
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including an allosteric BCR-ABL inhibitor, a small-molecule GLP-1 receptor agonist, a THR-β agonist, and a preclinical GIPR modulator discovery effort, prioritizing a GIPR antagonist nomination candidate. For more information, please visit: www.ternspharma.com.
Contacts for Terns
Investors
Justin Ng
investors@ternspharma.com
Media
Jenna Urban
Berry & Company Public Relations
media@ternspharma.com
FAQ
How many stock options did Terns Pharmaceuticals (TERN) grant to its new employee in February 2025?
What is the exercise price for TERN's February 2025 employee stock options?
What is the vesting period for TERN's February 2025 employee stock options?
How long is the term of the stock options granted by TERN in February 2025?
